COMPANY
Sutro Biopharma
Sutro Biopharma, Inc is a public biotechnology company headquartered in South San Francisco, California focused on clinical stage drug discovery, development and manufacturing company. From company website Source · Oct 12, 2026
Since the raise (Feb 10, 2026): 6 of 6 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| DIRECTOR, CLINICAL DATA MANAGEMENT | South San Francisco, California | Not stated | Oct 12, 2026 |
| SENIOR BIOSTATISTICIAN | South San Francisco, California | Not stated | Oct 12, 2026 |
| CONTROLLER | South San Francisco, California | Not stated | Oct 10, 2026 |
| SENIOR DIRECTOR, INFORMATION TECHONOLOGY | South San Francisco, California | Not stated | Oct 9, 2026 |
| SENIOR SCIENTIST, BIOANALYTICS | South San Francisco, California | Not stated | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (6 open jobs at last check). source ↗
- Trial start 1: Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic source ↗
- Raise Follow-on offering: $110M (total, as published), announced Feb 10, 2026. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 1: A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer source ↗
- Trial start Phase 1/Phase 2: Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML source ↗
- Trial start Phase 2: Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer source ↗
- Trial start Phase 2/Phase 3: REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian T source ↗
- Trial start Phase 1: A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer source ↗
- Trial start Phase 1: Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers source ↗
- Trial start Phase 1: Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies source ↗
Upcoming milestones
- 2027-12 (ESTIMATED) · Phase 1 · A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer · NCT07227168
- 2028-02 (ESTIMATED) · 1 · Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic · NCT07807345
Open jobs 6
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| DIRECTOR, CLINICAL DATA MANAGEMENT | South San Francisco, California | Not stated | Oct 12, 2026 | Senior |
| SENIOR BIOSTATISTICIAN | South San Francisco, California | Not stated | Oct 12, 2026 | Senior |
| CONTROLLER | South San Francisco, California | Not stated | Oct 10, 2026 | Senior |
| SENIOR DIRECTOR, INFORMATION TECHONOLOGY | South San Francisco, California | Not stated | Oct 9, 2026 | Senior |
| SENIOR SCIENTIST, BIOANALYTICS | South San Francisco, California | Not stated | Oct 9, 2026 | Senior |
| LOGISTICS MANAGER | South San Francisco, California | Not stated | Oct 9, 2026 | Mid |
Funding
- Follow-on offering: $110M (total, as published), announced Feb 10, 2026. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 8
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | 1 | Not yet recruiting | Sep 14, 2026 | 2028-02 (estimated) |
| NCT07227168 | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Phase 1 | Recruiting | Nov 7, 2025 | 2027-12 (estimated) |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | Phase 2/Phase 3 | Terminated | Jul 12, 2023 | Aug 26, 2025 (actual) |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | Phase 1 | Terminated | Mar 22, 2022 | Jun 1, 2025 (actual) |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | Phase 1/Phase 2 | Terminated | Dec 4, 2024 | Jun 1, 2025 (actual) |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Aug 21, 2024 | May 1, 2025 (actual) |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | Phase 1 | Completed | Feb 1, 2019 | Jun 4, 2024 (actual) |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | Phase 1 | Completed | Feb 22, 2018 | Feb 15, 2024 (actual) |
Connect
See your connections at Sutro Biopharma on LinkedIn (search by name, results not checked)